BERLIN, Germany, July 12, 2022 / B3C newswire / -- Granite Bio, a Swiss biotech company built through Versant Venture's discovery engine Ridgeline Discovery, and ProBioGen announced the closure of a Master Services Agreement to support the development of Granite Bio's mAb pipeline.
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. By using the DirectedLuck® transposase, ProBioGen can easily and efficiently start cell line development with multiple candidates, from which one selected candidate will finally be further pursued in CMC activities. Based on ProBioGen's proprietary media platform and USP/DSP platform processes, the development will focus on their adaption to the candidate's specific requirements.
Alexander Mayweg, Chairman of the Board of Granite Bio AG/Ridgeline Discovery: "In addition to ProBioGen's proven expertise in cell line and CMC development, it was their proprietary technologies and flexibility that enabled a tailored start of the project and convinced us to select ProBioGen as a partner for our lead candidate."
"With an experienced and professional team at Granite Bio, we are very much looking forward to collaborating on this project and to enable Granite Bio to advance their molecule to clinical testing," added Dr. Lutz Hilbrich, Chief Executive Officer at ProBioGen.
ProBioGen is a Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins.
Combining both state-of-the-art development services, based on ProBioGen's CHO.RiGHT® expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with
Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies
are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen has been operational for more than 25 years. At three locations in Berlin, more than 250 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work.
Dr. Gabriele Schneider
Chief Business Officer
Keywords: Cell Line; Cell Culture Techniques; Culture Media; Cell Proliferation; Cell Line Development; Cells, Cultured; Transposases; Transgenes; Genetic Vectors; Epigenesis, Genetic; Technology; Recombinant Proteins; Biological Products; Productivity; Bioreactors; Commerce; Germany
Published by B3C newswire